August 15, 2018
1 min read

Natera and Fox Chase Cancer Center partner to assess customized circulating tumor DNA assay

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Natera Inc. has announced it will partner with Fox Chase Cancer Center to assess the company’s Signatera customized circulating tumor DNA assay for recurrence monitoring of kidney cancer.

The study, led by Philip Abbosh, MD, PhD, an assistant professor in the Molecular Therapeutics Program at Fox Chase Cancer Center, will analyze biological specimens collected and banked from 49 patients diagnosed with kidney cancer, including a group of patients whose cancer recurred and a group whose cancer did not recur after 3 years or more. According to a press release from Natera, the study will use the company’s proprietary customized assay and next-generation sequencing-based technology to determine whether Signatera can be used to distinguish between the recurring and non-recurring kidney cancer cases.

“There is a paucity of data for circulating tumor DNA in kidney cancer. This research study will explore a novel approach for disease recurrence and treatment response monitoring in kidney cancer, since existing methods have limitations with sensitivity and specificity,” Abbosh said in the release. “Determining the relationship between kidney cancer genetic profiles and prognosis including recurrence using the Signatera assay has great potential to improve patient care by detecting cancer recurrence earlier, assisting adjuvant therapy decision-making, determining treatment effects and assessing the need for intervention during follow-up.”

C. Jimmy Lin, MD, PhD, MHS, chief scientific officer of oncology at Natera, said this kidney cancer study joins several research collaborations the company has established in the past 18 months involving a variety of cancer types, including breast, bladder, colorectal and lung cancers.

C. Jimmy Lin

“We look forward to working with Fox Chase Cancer Center,” Lin said in the release. “We expect that this study, along with our ongoing research efforts in other cancer types, will help us move toward clinically validating Signatera, with the goal of enabling more precise monitoring, better determination of prognosis and individualized treatment of disease.”